LL

LLY

NYSE

Eli Lilly and Company

Healthcare
Drug Manufacturers - General
United States
1386.83USD
-28.72 (-2.03%)
Market Cap: 1.26T USD

Revenue and Net Income

Values in USD

Income Statement

Values in USD

Financial itemTTMSep 30, 2026Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Total Revenue
86.46B65.18B45.04B34.12B28.54B
Cost of Revenue
14.15B11.05B8.42B7.08B6.63B
Gross Profit
72.31B54.13B36.63B27.04B21.91B
Operating Expense
28.00B24.43B19.59B16.72B13.63B
Operating Income
44.31B29.70B17.04B10.32B8.28B
Net Non Operating Interest Income Expense
——-605.40M-312.30M-268.80M
Other Income Expense
-9.55B-3.96B-4.36B-3.77B-1.21B
Pretax Income
34.77B25.73B12.68B6.55B6.81B
Tax Provision
7.19B5.09B2.09B1.31B561.60M
Net Income Common Stockholders
27.58B20.64B10.59B5.24B6.24B
Diluted NI Available to Com Stockholders
27.58B20.64B10.59B5.24B6.24B
Basic EPS
30.8523.0711.805.836.57
Diluted EPS
30.8122.9511.715.806.57
Basic Average Shares
893.63M894.80M897.54M899.38M950.18M
Diluted Average Shares
895.33M899.30M904.06M903.28M950.18M
Total Expenses
42.15B35.48B28.00B23.80B20.26B
Net Income from Continuing & Discontinued Operation
27.58B20.64B10.59B5.24B6.24B
Normalized Income
35.07B23.36B14.05B8.33B7.68B
Interest Income
——175.20M173.60M62.80M
Interest Expense
——780.60M485.90M331.60M
Net Interest Income
——-605.40M-312.30M-268.80M
EBIT
44.31B29.70B17.04B10.32B7.14B
EBITDA
46.49B31.69B18.81B11.85B8.66B
Reconciled Cost of Revenue
14.15B11.05B8.42B7.08B6.63B
Reconciled Depreciation
2.17B2.00B1.77B1.53B1.52B
Net Income from Continuing Operation Net Minority Interest
27.58B20.64B10.59B5.24B6.24B
Total Unusual Items Excluding Goodwill
-9.44B-3.39B-4.14B-3.87B-1.56B
Total Unusual Items
-9.44B-3.39B-4.14B-3.87B-1.56B
Normalized EBITDA
55.93B35.09B22.95B15.72B10.22B
Tax Rate for Calcs
0.210.200.160.200.08
Tax Effect of Unusual Items
-1.95B-671.52M-682.55M-777.47M-129.80M

Key Statistics

Valuation

Market Cap (USD)1.26T
Market Cap (Local)1.26T
P/E (TTM)45.72
P/S (TTM)14.58
MC/EBITDA27.12

Volume & Shares

Last Volume2.64M
Avg Vol (10D)2.75M
Avg Vol (30D)2.53M
Avg Vol (90D)2.55M
Shares Outstanding890.75M

Growth Indicators

Revenue TTM/Ann1.33
Net Income TTM/Ann1.34
EBITDA TTM/Ann1.47
Gross Profit TTM/Ann1.34
Operating Inc TTM/Ann1.49

Currency & Exchange

Trading CurrencyUSD
Financial CurrencyUSD
Trading/USD Rate1.00
Financial/USD Rate1.00
ExchangeNYSE

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes Jardiance, Mounjaro, and Trulicity for type 2 diabetes and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma Erbitux for colorectal cancers and head and neck cancers Inluriyo for breast cancer Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma Retevmo for the treatment of metastatic NSCLC TYVYT for classic hodgkin's lymphoma and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss Olumiant Omvoh and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss and Chugai Pharmaceutical Co., Ltd for orforglipron strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases BioArctic AB (publ) for new treatment QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.